This medicine is now known as Angiotensin 1-7.

On 19 February 2014, orphan designation (EU/3/14/1241) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of Duchenne muscular dystrophy.

In December 2015, Gregory Fryer Associates Ltd changed name to Envigo Pharma Consulting Ltd.

The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.

The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited in January 2020.

Key facts

Active substance
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rapport Global Strategic Services Ireland Limited
22 Northumberland Road 
Dublin 4
Tel: +353 1 671 5 564

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating